A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-324 in Adult Participants With Hepatocellular Cancer (HCC) or Squamous-Cell Non-Small Cell Lung Cancer (LUSC)
NCT06858813
This study is recruiting at 10 US sites in 6 states, according to its ClinicalTrials.gov record last updated .
Summary
HCC is a common cancer worldwide and a leading cause of cancer-related death. Lung cancer is the most frequently diagnosed cancer in the world, and the leading cause of cancer deaths. The purpose of this study is to assess adverse events and change in disease activity when ABBV-324 is given to adult participants to treat hepatocellular cancer (HCC) or squamous-cell non-small cell lung cancer (LUSC). ABBV-324 is an investigational drug being developed for the treatment of HCC and LUSC. Study doctors put the participants in groups called arms.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Hepatocellular Cancer
- Squamous-Cell Non-Small Cell Lung Cancer
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- AbbVie
- Last updated on ClinicalTrials.gov
- September 22, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 5
- City of Hope National Medical Center /ID# 270526 · Duarte, CA
- City of Hope - Orange County Lennar Foundation Cancer Center /ID# 276120 · Irvine, CA
- USC Norris Comprehensive Cancer Center /ID# 271573 · Los Angeles, CA
- University Of California Irvine Medical Center /ID# 270507 · Orange, CA
- UCLA - Santa Monica /ID# 275995 · Santa Monica, CA
Illinois · 1
- University of Chicago Medical Center /ID# 270517 · Chicago, IL
Missouri · 1
- Washington University /ID# 275757 · St Louis, MO
New York · 1
- Memorial Sloan Kettering Cancer Center /ID# 271228 · New York, NY
Pennsylvania · 1
- Thomas Jefferson University Sidney Kimmel Cancer Center /ID# 276269 · Philadelphia, PA
Tennessee · 1
- SCRI Oncology Partners /ID# 272750 · Nashville, TN
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.